Loading...
XNASTRVN
Market cap1mUSD
Dec 24, Last price  
1.80USD
1D
14.65%
1Q
-53.85%
Jan 2017
-98.78%
IPO
-98.91%
Name

Trevena Inc

Chart & Performance

D1W1MN
XNAS:TRVN chart
P/E
—
P/S
0.50
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-24.14%
Rev. gr., 5y
-11.43%
Revenues
3m
P
2,421,381807,595134,98006,250,0003,750,00005,732,00031,0003,069,000567,000-418,0003,125,000
Net income
-40m
L-24.93%
-15,810,004-15,635,658-23,251,435-49,700,875-50,528,240-102,994,000-71,865,000-30,784,000-28,056,000-29,369,000-51,160,000-53,667,295-40,289,000
CFO
-33m
L-35.83%
-13,281,590-14,805,153-24,239,230-39,777,930-40,074,960-91,554,000-71,255,000-25,375,000-23,667,000-21,394,000-50,197,000-51,477,000-33,034,999
Earnings
Mar 31, 2025

Profile

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
URL
https://www.trevena.com/
IPO date
Jan 31, 2014
Employees
35
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,125
-847.61%
(418)
-173.72%
567
-81.52%
Cost of revenue
18,003
21,229
52,492
Unusual Expense (Income)
NOPBT
(14,878)
(21,647)
(51,925)
NOPBT Margin
5,178.71%
Operating Taxes
318
(3)
(428)
Tax Rate
NOPAT
(15,196)
(21,644)
(51,497)
Net income
(40,289)
-24.93%
(53,667)
4.90%
(51,160)
74.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,548
9,607
7,742
BB yield
-2,163.89%
-2,374.81%
-203.48%
Debt
Debt current
1,012
899
792
Long-term debt
40,669
25,201
13,410
Deferred revenue
Other long-term liabilities
5,475
5,483
Net debt
8,166
(14,180)
(54,032)
Cash flow
Cash from operating activities
(33,035)
(51,477)
(50,197)
CAPEX
(41)
(28)
(16)
Cash from investing activities
(41)
18
(16)
Cash from financing activities
26,311
23,505
7,734
FCF
(14,344)
(20,809)
(50,672)
Balance
Cash
32,975
38,320
66,923
Long term investments
540
1,960
1,311
Excess cash
33,359
40,301
68,206
Stockholders' equity
(588,044)
(547,763)
(493,937)
Invested Capital
622,107
588,610
565,667
ROIC
ROCE
EV
Common stock shares outstanding
739
283
261
Price
0.72
-49.50%
1.43
-90.18%
14.56
-72.78%
Market cap
534
31.92%
405
-89.37%
3,805
-65.17%
EV
8,700
(13,775)
(50,227)
EBITDA
(14,544)
(21,265)
(51,497)
EV/EBITDA
0.65
0.98
Interest
1,256
1,000
Interest/NOPBT